Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of ...

The MarketWatch News Department was not involved in the creation of this content.-- Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associate ...

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric ...

Discover Rhythm Pharmaceuticals’ Q3 2025 earnings insights, IMCIVREE launch updates, regulatory milestones, and global growth plans.

Research led by the University of Jyväskylä has found that personalized interactive music systems – smart technologies that adapt rhythm and tempo to ...

Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsVipin Garg - President, CEO & DirectorLinda Richardson ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, adding to the body of evidence supporting this potential treatment option.1 ...

Research led by the University of Jyväskylä has found that personalized interactive music systems—smart technologies that ...

This study links childhood gut microbiome to brain connectivity, highlighting its role in internalizing symptoms like anxiety ...

Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...